GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 34 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,915 | -78.1% | 665 | -71.1% | 0.00% | – |
| Q2 2023 | $8,756 | -42.1% | 2,298 | -71.7% | 0.00% | – |
| Q1 2023 | $15,111 | +53.4% | 8,124 | +89.7% | 0.00% | – |
| Q4 2022 | $9,851 | -89.8% | 4,283 | -85.8% | 0.00% | – |
| Q3 2022 | $97,000 | -69.9% | 30,241 | -48.3% | 0.00% | – |
| Q2 2022 | $322,000 | +61.0% | 58,460 | -32.2% | 0.00% | – |
| Q1 2022 | $200,000 | -61.7% | 86,204 | -0.2% | 0.00% | – |
| Q4 2021 | $522,000 | +56.3% | 86,342 | +258.4% | 0.00% | – |
| Q3 2021 | $334,000 | – | 24,092 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 10,881,144 | $31,337,695 | 3.43% |
| Sio Capital Management, LLC | 2,081,216 | $5,993,902 | 1.86% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,375,000 | $3,960,000 | 1.58% |
| TCG Crossover Management, LLC | 3,038,889 | $8,752,000 | 1.29% |
| Logos Global Management LP | 2,525,000 | $7,272,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,531,497 | $4,410,711 | 0.80% |
| Orbimed Advisors | 9,308,726 | $26,809,131 | 0.57% |
| GREAT POINT PARTNERS LLC | 579,667 | $1,669,441 | 0.30% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $28,517,587 | 0.17% |
| TANG CAPITAL MANAGEMENT LLC | 159,087 | $458,171 | 0.06% |